Disease landscape
Lymphoma
A high level of restrictions in diagnosis and access to lymphoma treatment has been identified in the Visegrád (V4) countries as measured in the GAP score. Scores vary widely between countries, with Poland and the Czech Republic scoring more than 55 points, more than twice as high as the lowest scoring country, Hungary. The main reason for limited V4 performance is the lack of reimbursement or the high reimbursement restrictions for most drugs included in analysis, as well as the low share of patients treated with CAR-T therapy.
Cross-Country
General GAP for Lymphoma
Compliance with guidelines
Of the 28 drugs recommended by the NCCN clinical practice guidelines, 50-60% are available in the V4 countries with the exception of Hungary, where the public finance availabulity only applies to less than 30% of the recommended therapies.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
car-t
Drug access
Number of patients treated (2023)
Drug access
POPULATION treated (%) with car-t
Main issues
- The average time to reimbursement for lymphoma drugs in the V4 countries is 3.3 years. The difference between the shortest and the longest mean time to reimbursement among the states is 0.9 years.
- The proportion of patients in the target population treated with CAR-T is very low, estimated to be around 15% in Poland and 7% in Czechia in 2023, while the therapy was not available in Hungary and Slovakia.
- Disability adjusted life-years (DALY) burden in the V4 countries is about 10-15% lower than the EU average. As in the EU as a whole, the stabilization of burden was observed in the V4 countries in 2005-2019.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).